Efficacy and Safety of Benralizumab for Korean Patients With Severe, Uncontrolled Eosinophilic Asthma

PURPOSE: In the Phase III SIROCCO trial (NCT01928771), benralizumab significantly reduced asthma exacerbations and improved lung function and symptoms for patients with severe, uncontrolled eosinophilic asthma. The aim of this subgroup analysis was to evaluate efficacy and safety of benralizumab for...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Allergy Asthma Immunol Res
Main Authors: Park, Hae-Sim, Lee, Sang Haak, Lee, Sook Young, Kim, Mi-Kyeong, Lee, Byung Jae, Werkström, Viktoria, Barker, Peter, Zangrilli, James G.
Formato: Artigo
Idioma:Inglês
Publicado em: The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease 2019
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6557768/
https://ncbi.nlm.nih.gov/pubmed/31172719
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4168/aair.2019.11.4.508
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados